ADVERTISEMENT
Amivantamab Plus Chemotherapy Demonstrates Antitumor Activity in Metastatic Colorectal Cancer
Findings From the Phase 1b/2 OrigAMI-1 Study
Findings From the Phase 1b/2 OrigAMI-1 Study
Filippo Piertrantonio, MD, National Cancer Institute of Milan, Italy, discusses results from the OrigAMI-1 study. Results determined that amivantamab plus FOLFOX or FOLFIRI demonstrates antitumor activity and manageable safety in patients with RAS/RAF-wild type metastatic colorectal cancer (CRC).
Dr Pietrantonio presented these results at the 2024 European Society of Medical Oncology (ESMO) Congress in Barcelona, Spain.
Source:
Pietrantonio F, Ho GF, Su YL, et al. Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase 1b/2 study. Presented at 2024 ESMO Congress. September 13-17, 2024. Abstract 513MO
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement